125I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer
| Autor: | Rahul D. Tendulkar, James Ulchaker, Chandana A. Reddy, Ahmed Halima, Kenneth Angermeier K, Omar Y. Mian, Eric A. Klein, Jay P. Ciezki, Timothy D. Smile, Steven C. Campbell, Ryan X. Zhang, Kevin L. Stephans, M.C. Tom |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Brachytherapy Interstitial brachytherapy Urology medicine.disease Androgen deprivation therapy Prostate cancer Oncology Older patients Cox proportional hazards regression medicine Radiology Nuclear Medicine and imaging Prospective cohort study business Prostate brachytherapy |
| Zdroj: | Brachytherapy. 21:85-93 |
| ISSN: | 1538-4721 |
| DOI: | 10.1016/j.brachy.2021.09.001 |
| Popis: | PURPOSE/OBJECTIVE(S) To determine if patients with unfavorable intermediate-risk (UIR), high-risk (HR), or very high-risk (VHR) prostate cancer (PCa) treated with 125I interstitial brachytherapy benefit from androgen deprivation therapy (ADT). MATERIALS/METHODS We reviewed our institutional database of patients with UIR, HR, or VHR PCa, per 2018 NCCN risk classification, treated with definitive 125I interstitial brachytherapy with or without ADT from 1998-2017. Outcomes including biochemical failure (bF), distant metastases (DM), and overall survival (OS) were analyzed with the Kaplan-Meier method and Cox proportional hazards regression. PCa-specific mortality (PCSM) was analyzed with Fine-Gray competing-risk regression. RESULTS Of 1033 patients, 262 (25%) received ADT and 771 (75%) did not. Median ADT duration was 6 months. By risk group, 764 (74%) patients were UIR, 219 (21%) HR, and 50 (5%) VHR. ADT was more frequently given to HR (50%) and VHR (56%) patients compared to UIR (16%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|